Free Trial

Wedbush Forecasts Arcus Biosciences' Q1 Earnings (NYSE:RCUS)

Arcus Biosciences logo with Medical background
Remove Ads

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities researchers at Wedbush increased their Q1 2025 earnings per share estimates for shares of Arcus Biosciences in a note issued to investors on Tuesday, February 25th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($1.08) per share for the quarter, up from their previous forecast of ($1.31). Wedbush has a "Outperform" rating and a $36.00 price target on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences' Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($4.16) EPS, FY2026 earnings at ($3.93) EPS, FY2027 earnings at ($3.24) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $3.71 EPS.

Several other equities research analysts have also commented on the stock. Bank of America cut their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. Morgan Stanley decreased their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. Finally, HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $30.25.

Remove Ads

View Our Latest Stock Analysis on RCUS

Arcus Biosciences Stock Performance

Shares of NYSE RCUS traded down $0.85 during midday trading on Friday, reaching $9.65. 969,467 shares of the stock were exchanged, compared to its average volume of 710,609. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a 50-day simple moving average of $13.26 and a two-hundred day simple moving average of $15.36. Arcus Biosciences has a twelve month low of $9.65 and a twelve month high of $19.69. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -3.06 and a beta of 0.84.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the company's stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Yasunori Kaneko acquired 20,000 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average cost of $10.06 per share, with a total value of $201,200.00. Following the completion of the purchase, the director now directly owns 28,400 shares in the company, valued at $285,704. This represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Institutional Investors Weigh In On Arcus Biosciences

A number of large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Arcus Biosciences by 2.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock valued at $506,000 after purchasing an additional 833 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Arcus Biosciences by 2.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company's stock valued at $471,000 after buying an additional 843 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Arcus Biosciences by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company's stock valued at $668,000 after buying an additional 1,117 shares during the period. R Squared Ltd purchased a new position in shares of Arcus Biosciences during the fourth quarter valued at approximately $26,000. Finally, Teacher Retirement System of Texas boosted its position in Arcus Biosciences by 19.2% during the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock worth $223,000 after acquiring an additional 2,410 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.

Arcus Biosciences Company Profile

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Further Reading

Earnings History and Estimates for Arcus Biosciences (NYSE:RCUS)

Should You Invest $1,000 in Arcus Biosciences Right Now?

Before you consider Arcus Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.

While Arcus Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads